---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-051576"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:49:05.576834+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025

## Summary
- Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.
- Current CMO Jean-Marie Cuillerot departs on April 9, 2025.
- Dr. Mirza will lead Phase 2b trial of ACR-368 for endometrial cancer and Phase 1 trial of ACR-2316.
- He previously served as chief oncologist at Copenhagen University Hospital and medical director of NSGO CTU.

## SEC filing metadata
- accession: 0000950170-25-051576
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/0000950170-25-051576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/acrv-20250407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-051576
- JSON: https://secwatch.observer/filing/0000950170-25-051576.json
- Plain text: https://secwatch.observer/filing/0000950170-25-051576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.